Introduction
The completion of the consensus sequence of the human genome (Lander, et al., 2001; Venter, et al., 2001 ) ushered in the "post-genomic era" of science -that is, experiments could be designed using the reference sequence of the genome without need for additional sequencing efforts. Subsequent publication of the human haplotype map, an analysis of sequence diversity in 270 individuals from 4 ancestral populations (International HapMap Consortium, 2003 , 2004 Frazer, et al., 2007) , provided knowledge for building reagents for further genetic analyses. The knowledge and sequence information provided the resources to analyze the genetic contribution to virtually all measurable phenotypes. These efforts and the resulting databases complemented the long-standing efforts by geneticists to locate, identify, and characterize mutations that cause monogenic and polygenic diseases in humans, an effort begun by McKusick and colleagues in the 1950s (reviewed in McKusick, 2006) and now catalogued in the Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim; Hamosh, et al., 2005) and the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk; Stenson, et al., 2008 van Baal, et al., 2007) and GAD (the Genetic Association Database http://geneticassociationdb.nih.gov/; Becker, et al., 2004) , are repositories for data from population studies associating genetic variation with phenotypes. Most of these databases are studyoriented and analyze existing polymorphisms rather than focusing on the discovery of new genetic variants.
A large amount of other mutation or gene variation data, however, is likely to exist on servers in laboratories scattered throughout the world. Each of these databases may contain valuable data for other studies and for the medical practitioner. The Human Variome Project (HVP; http://www.humanvariomeproject.org/) was previously proposed to systematically collect mutations that cause human disease (Cotton, et al., 2007a; Cotton, et al., 2007b; Ring, et al., 2006) and create a cyber infrastructure to link locus specific databases (LSDBs). Local experts would curate individual LSDBs but each would have similar architecture, ontologies, and data elements allowing for interoperability. Links to national and international databases such as at the National Center for Biotechnology Information (NCBIhttp://www.ncbi.nlm.nih.gov/) and the European Bioinformatics Institute (EBI -http://www.ebi.ac.uk/) would consolidate the knowledge of the curation done by local experts. We report here the discussions and recommendations from the 2008 HVP planning meeting held in San Feliu de Guixols, Spain, in May 2008, to further the development of the HVP.
The theoretical rationale for re-sequencing genes from individuals in diverse populations is that the existing databases have focused primarily on Europeans and their descendants and are therefore a relatively narrow subdivision of the entire range of human genetic diversity. Published data supporting a concerted re-sequencing effort for monogenic and complex diseases come from independent and unlinked studies:
 The molecular basis of 2393 phenotypes was known as of September 2008 (http://www.ncbi.nlm.nih.gov/Omim/mimstats.html). Many monogenic diseases are caused by different mutations in one gene, and all monogenic diseases are known to have variable age of onset, severity and outcome (e.g., McKusick, 2007; Ropers, 2007) . Differences in monogenic disease phenotype may be caused by variations in location of mutations, by modifier genes that interact with the disease causing allele (McKusick, 2007) , and by gene-environment interactions (Ordovas and Corella, 2006) . Characterizing causative mutations in familial and sporadic cases in diverse populations is warranted for a full understanding of each disease.
 The molecular basis of over 3700 other phenotypes are either suspected to be Mendelian disorders or are unknown (http://www.ncbi.nlm.nih.gov/Omim/mimstats.html).
 Simple monogenic traits may be caused by different gene variants. The ability to hydrolyze lactose as an adult, which is called lactase persistence, occurs in ~30% of the world's population (Lomer, et al., 2008) . Expression of the lactase gene post-weaning has been associated with a C/T variant at position -13910 from the start of the lactase (LCT) gene in Finnish families and 236 individuals from 4 populations (Germany, Italy, South Korea and Finland) (Enattah, et al., 2002) . However, lactase persistence is associated with a different variant (G/C at -14010 from LCT) in Kenyans, Tanzanians, and Sudanese (Tishkoff, et al., 2007) . Other populations with higher percentages of individuals with lactose tolerance have not been analyzed (Montgomery, et al., 2007) . Variation in amounts of lactose required to induce intestinal bloating and diarrhea, severity, and age of onset are observed in reference populations (lactose intolerant) and in populations where the lactase persistence variants are more common (Lomer, et al., 2008; Montgomery, et al., 2007) . nonsynonymous changes including 11 alleles with frequencies <1% along with the common alleles p.A222V, p.E429A, and p.R594Q (Marini, et al., 2008) . Increased levels of folate restored MTHFR activity to the normal range in 4 of the 5 variants. The sequence heterogeneity and remediation of enzyme activity by folate supports a greater emphasis on the ~600 cofactor dependent enzymes in the human proteome. Since many cofactors are derived from diet, such studies may identify individuals who require higher concentrations of vitamins for optimal health.
Analyses of populations using HapMap data or their derivative reagents also provide justification for the need to re-sequence genes in diverse populations.
 Published HapMap data analyzed by a novel algorithm identified chromosomal regions with a high Fst (Fixation index, a measure of population differentiation) between three ancestral populations (European, Chinese and African) (Myles, et al., 2008b) . These regions encoded genes involved in carbohydrate metabolism, skeletal development, and pigmentation. Such allele frequency differences may explain, for example, the differential effect in incidence of obesity and type 2 diabetes between Europeans and Pima Indians who consume similar Western diets (Schulz, et al., 2006) .  Twenty-five SNPs linked to 6 chronic diseases in genome wide association studies (GWAS) were analyzed in ~1000 individuals from 53 populations (Myles, et al., 2008a) . Several risk alleles were absent from some populations and several were present at 100% frequency indicating that the allele may contribute uniquely to disease in the European population. Other polymorphisms in these genes or in other genes within the non-European populations are likely to contribute to disease incidence and severity.
 Allele frequencies of 873 tag SNPs in 82 candidate genes involved in hypertension, type 2 diabetes, obesity, dyslipidemia or metabolic syndrome varied in 54 populations (Hancock, et al., 2008) . Some of these genes were linked to adaptation to cold climates and others likely to selection by other environmental factors. Exposure to infectious agents such as malaria (Kwiatkowski, 2005) , high altitude (Beall, 2007) and the food environment (Perry, et al., 2007) have also been shown to select for certain genotypes.
 Culture is also known to influence allele frequencies among populations. A gradient of genotypes exists from northwest to southeast in Europe (Price, et al., 2008 ). At a fine mapping level, allele frequencies mirror geography, and by inference, national culture, within Europe (Lao, et al., 2008; .
Variation at the genomic and gene levels demonstrates that existing data and reagents will not be sufficient to identify genes involved in maintaining health or those that contribute to the incidence and severity of disease. The newly initiated 1000 Genomes project (http://www.1000genomes.org), which is being organized by an international consortium, will employ genome-wide re-sequencing and targeted coding region sequencing in a total of approximately 1500 individuals from three human populations:
Europeans, Africans, and Asians (Lang, 2008; Siva, 2008) . Each of these populations will be represented by a number of sub populations consisting of approximately 100 individuals including Yoruba in Ibadan, Nigeria; Japanese in Tokyo; Chinese in Beijing; Utah residents with ancestry from northern and western Europe; Toscani in Italy; and other populations to be determined. The goal of this international effort is to characterize alleles with frequencies of approximately 1% genome-wide and less than 1% in coding regions. The phenotype of individuals sequenced in the project will not be analyzed. Hence, these data will be used for improving selection of reagents and designs for GWAS and will not be directly focused on identification of disease causing genes. Further information is available from the project website referenced above.
The Human Variome Project
The Human Variome Project differs from these other efforts in developing and fostering an international effort to systematically identify genes, their mutations, and their variants associated with phenotypic variability and indications of human disease. The HVP is an international effort linking clinical, medical, and research laboratories for developing knowledge housed within linked databases. This knowledge would be accessible to the research and medical communities to improve research strategies and clinical medical practice. The key objectives of the project are described in Box 1. An example of the need for the HVP as applied to neurological disorders has recently been published (Cotton, et al., 2008) .
The HVP Planning Meeting conducted concurrent meetings that discussed (i) classifying genetic variation from unlinked clinical medicine or research laboratories, (ii) capturing data from diagnostic and service laboratories, (iii) assessment of pathogenicity, (iv) data transfer, (v) data integration access, (vi) funding and governance, (vii) emerging countries' initiative and involvement, (viii) ethics: existing and anticipated concerns, (ix) attribution and publication, and (x) pilot projects (Table 1) . Reports for classifying and capturing genetic variation from laboratories (i.e., committee reports i and ii) have been combined for sake of brevity. Detailed reports for these sessions are provided in the supplementary information. Below are synopses of the main outcomes and recommendations.
Classifying Genetic Variation from Unlinked Clinical Medicine, Research, or Service Laboratories
The cyber infrastructure for biological data is extensive (Stein, 2008) but still not fully integrated or developed. The HVP is relying upon these databases for data element definition, storage, management, retrieval, and nomenclature. For example, the NCBI provides a gene-centric index for mutation nomenclature, Human Genome Organization (HUGO; http://www.hugo-international.org/) has a naming scheme for genes, and the Human Genome Variation Society (HGVS; http://www.hgvs.org/; Cotton and Horaitis, 2000) provides for naming of mutations. The Cancer Bionformatics Grid (caBIG -https://cabig.nci.nih.gov/; Fenstermacher, et al., 2005) exemplifies the need for interoperability, common languages, data standards and sharing. In addition to the disease-specific (e.g., caBIG) and international databases, LSDBs in individual laboratories and institutes exist but are not easily linked to the rest of the bioinformatic community.
While the data management infrastructure continues to expand, curated genetic data are scattered: no coordinated effort exists to harness and harmonize these efforts, data and knowledge. Gene mutation and variation data are generated from and used by diagnostic, epidemiological experiments, research laboratories, and clinicians, each of which has different missions, ability or willingness to curate information, and resources (Table 2) .
Since clinical laboratories are not required or encouraged to deposit genotype or phenotype data into publicly available databases, data sharing ranges from complete to none. Efforts to encourage and develop ongoing data collection have begun and range from commercial enterprises to funded grant programs (Table 3) . Each of these programs is developing unique solutions for the barriers of time, cost, concerns of patient confidentiality, IRB requirements, maintenance of quality assurance, and difficulties in obtaining clinical information from referring centers. These challenges reinforce the concept that clinical laboratories should not be expected to develop and curate public databases. However, clinical laboratories should be expected to contribute data. Developing a standard open software suite such as the Leiden Open Variation Database (LOVD; http://www.lovd.nl ; Fokkema, et al., 2005) for these initiatives will allow existing tools, for example the Universal Mutation Database (UMD; http://www.umd.be/; Beroud, et al., 2000) software, to query across the cyberspace of LSDBs to retrieve and analyze data (Table 3) . Relying upon a common database design, language and interoperability will enforce quality standards across clinical and research laboratories. Nevertheless, clinical and research laboratories may have processes and quality measures which would require a "data warning" for select entries or datasets. Some of the issues and requirements to initiate adoption of these ideas are described in Box 2. Once these individual LSDBs are developed and curated locally, ethically appropriate data elements can be deposited in national or international databases (NCBI or EBI).
Pathogenicity and Clinical Utility
Understanding the consequences of genetic variation depends upon the simultaneous collection and documentation of phenotypic data for each variant (e.g., Cotton et al., 2007a; Crawford and Nickerson, 2005; Kaput, 2008; Kaput et al., 2005; Ring et al., 2006; Taylor et al., 2001) . The correlation between genome and phenotype (pathogenicity) is the basis for the clinical benefit. The two broad principles for assessing pathogenicity or phenotype linked to a genetic variant are that (i) multiple data elements must be integrated and (ii) data elements and the integration process must have standards, validation, quantification and transparency (Box 3).
The omics sciences are now capable of generating large but disparate (e.g., genomic vs metabolomic) datasets that may be used in research but also clinical applications. Although assessing pathogenicity will be an ongoing, iterative process, several specific recommendations are warranted:
Genetic and Genomic Data. Gene marker analysis is an important step in the clinical diagnosis of pediatric and adult genetic disorders. The issues associated with clinical genetic testing are well recognized for inherited cancer syndromes, where missense variants represent 10-30% of test results (e.g., (Eisinger, 2008; Metcalfe, et al., 2008; Stoffel, et al., 2008) ). Many of these variants are classified as having an uncertain effect unless strong genetic epidemiologic and/or functional evidence exists associating them with the syndrome. The Breast Cancer Information Consortium (BIChttp://research.nhgri.nih.gov/bic/) classifies BRCA1 and BRCA2 variants as pathogenic only if the probability of pathogenicity, usually based on statistical genetic approaches is, definitely pathogenic Hence, complete re-sequencing of a gene proven or suspected to be involved in monogenic and polygenic diseases will be required to determine causal linkages between genes and phenotype.
Standardizing Existing Clinical Phenotype and Pathology. A fundamental problem with assessing phenotypes is the diversity of the underlying molecular pathways that cause disease, and as a consequence the heterogeneity in clinical manifestations, age of onset, severity, complications, and age of death. Other groups (Kaput, et al., 2005; Kathiresan, et al., 2008; Makinen, et al., 2008; Rosenzweig, et al., 2002; Wong, 2006; Zaninotto, et al., 2007) have proposed using disease as a classifier (e.g., type 2 diabetes), but rely on quantitative measures of phenotype (e.g., fasting glucose, fasting insulin) as a means to reduce subjective assignments of disease (Tracy, 2008) . Since the HVP seeks to collect data from laboratories and clinics, phenotype templates are needed to define ranges of (i) minimum sets of clinical data, (ii) range of subset data, and (iii) maximum datasets. Such hierarchical template structures will allow scientists in all countries to participate in data and sample collection. Developing the LOVD/UMD tools (Table 3 and below) for the HVP will also require a means to validate data and data quality prior to implementation across laboratories. Clinical and pathology data standards must be developed by experts in each genetic disorder for interpreting the effects of genetic variation.
Standards linking in vitro functional studies with clinical results. If a cellular function can be
established that appears to correlate with the clinical syndrome, then in vitro assays could be used to classify whether a variant retains or loses function. Standards for performing and interpreting the assays are crucial if these methods are to be accepted as a mechanism for classifying variants clinically . In cancer genetics, the correlation of mismatch repair defects with Lynch syndrome (Hereditary Non-Polyposis Colorectal Cancer) is probably the most well-established example (Ou et al., 2007) ; even so, the principle that multiple data elements must be integrated to achieve classification should be respected.
Computational studies. Multiple studies in recent years have confirmed the value of comparative sequence analysis in helping to predict whether a missense variant is pathogenic or not (reviewed in Tavtigian et al., 2008) . However, the issues of standards, validation, and transparency also apply to computational methods. Most importantly, the quality of a multiple sequence alignment is critical to their accuracy (Ahola et al., 2006; Ahola et al., 2008) . The choice of ortholog sequences that is used, the quality of cDNA or genomic data, and the methods used to construct the alignment are all important features.
Computational Studies -Predictive Algorithms. Some methods have already been validated on curated data sets of variants, establishing their Negative Predictive Value (NPV, the proportion of predictions of "neutral" that are actually neutral) and Positive Predictive Value (PPV, the proportion of predictions of "pathogenic" that are actually pathogenic) (Chan et al., 2007; Chao et al., 2008) . However, several of the more commonly used algorithms have been updated. Algorithms exist for coding region variants and predictions of altered splice sites (Nalla and Rogan, 2005; Spurdle et al., 2008) . New methods, including both rule-based and machine-learning approaches, are being developed , and in the future, algorithms to assess other non-coding functions of DNA are anticipated.
Data Transfer and Databasing -Gene and Locus Specific Databases
Historically, gene variation data were first collected for specific gene(s) causing a Mendelian disorder or a change in the phenotype. These listings usually were initiated and driven by the interests of an expert using the collection for research, clinical or diagnostic applications. Currently there are over 700 such 
Integrating Data and Providing Access
The breadth and depth of information available about human variation are rapidly expanding as new technologies (e.g., omics and imaging) analyze health and pathogenicities. Uncomplicated methods of access are needed for multiple user communities with differing expertise in genetics, clinical medicine, nutrition, physiology, and probably the public. Information generated by the HVP will have many of those dimensions, ranging from how variants are identified, the type of variant, the physiological parameters associated with the variant, and where and how records are maintained and accessed. For example, information for rare variants, SNPs, microsatellites, small insertions/deletions will range from reports of one variant in one individual, such as might be gathered from manual data entry and maintained in medical records, to large-scale screening of thousands of genomes in defined populations. How the data are represented will be a challenge since information will come from published literature or text-rich resources such as OMIM or GeneReviews (http://www.geneclinics.org/profiles/all.html; Pagon et al., 2002) , include explicit records in LSDBs and/or genome-wide resources such as dbSNP or genome browsers. The scope of the data, which includes locations of variants on reference sequences to phenotypes in humans and model organisms, increases the dimensionality. Hence, the scale of information for human genetic variation and linked phenotype can range from a single text document to petabytes of raw data derived from sequencing thousands of genomes to a high level of coverage and accuracy. Model databases capable of accessing known variants will be developed from pilot projects and provide a resource for clinicians, patient advocates, and the public (i.e., education).
Accessing known variants.
Given the dimensionality issues and the challenges they represent, the HVP will help develop an infrastructure to identify variants relative to a reference standard and allow facile linking of data with appropriate tools. Notification schemes would be developed to indicate missing data for each variant. The HVP is identifying a progression of doable tasks with milestones for each. For example, the HVP will link with one such effort, the on-going collaboration among GEN2PHEN (http://www.gen2phen.org), EBI, and NCBI to develop an international set of standard Locus Specific Genomic Sequence reference (LRGS/RefSeqGenehttp://www.gen2phen.org/docs/LRG_Specification_Summary_version_9.pdf). With that foundation in place, active LSDBs can report their variants in LRG/RefSeqGene coordinates to centralized databases (EBI/NCBI) to be accessioned to dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/; Sherry et al., 2001 ).
The scope of information to be centralized requires further debate, but could include items described in (Giardine et al., 2007) ) serving as a data collection center are being implemented.
Public education.
With the understanding that large data sets are only as useful as their ease of access, the HVP can also foster portal sites to help direct users to tools and resources of interest, and identify areas requiring additional development. Tutorials comparing and contrasting different resources might also be commissioned. Topics that must be addressed are how to access information in the published literature, the effect of variation on transcription, the significance of conserved non-coding regions on phenotypic variation, identification of mRNA splice sites, descriptions on the structure and maintenance of LSDBs, and strategies for interpreting the impact of single (e.g., SNPs) and multiple (e.g., haplotypes) variants in one allele or in multiple alleles on the phenotype of interest. The HVP intends to make greater efforts to educate the public about the project's importance and the benefits of research participation.
Attribution and Publication
A major barrier to the development of comprehensive analyses of human genetic variation, and therefore LSDBs, is the reward system for clinicians and academic researchers. Non-academic clinicians typically receive little or no credit for contributing to the scientific literature, and academic clinicians and basic researchers cannot easily persuade journals to publish the 50 th variant of a gene that has an observable effect on phenotype. These cultures may be difficult to change overnight, but specific steps could be instituted immediately to promote the submission of genotype -phenotype data to LSDBs and to "reward" contributions to team projects. Database entries could be a mandatory quality control standard for clinical laboratories and clinicians. For researchers, a publication or web-based system establishing microattribution and community annotation of mutations (e.g., http://www.wikigenes.org) and cited data will enable measurable contributions to the scientific knowledge base (Editorial, 2008; Hoffmann, 2008) .
Similarly, database-journals would also serve this task by providing a forum for publishing gene variation data that would be eventually deposited in the PubMed literature database. One such journal, the open access Human Genomics and Proteomics (HGP; http://www.sage-hindawi.com/journals/hgp), which is affiliated with FINDbase, will focus on studies characterizing causative mutation and/or biomarker frequency spectra. Accepted contributions including datasets will be linked in FINDbase and deposited in PubMed (Patrinos and Petricoin, 2009 ). Journals, tenure and promotion committees, and funding agencies would be encouraged to cite these contributions to and citations of LSDB and international national databases (Patrinos and Brookes, 2005) . The HVP recommends that researchers cite these attributions and citations in their curricula vitae to foster the transition of the academic culture. The same trend and recommendations for development of coherent tools are valid for the recognition of contribution to the setting, use and sharing of any bioresource such as biobanks (Cambon-Thomsen, 2003; Kauffmann and Cambon-Thomsen, 2008 ) and international efforts like P3G are being developed in the same spirit. (Knoppers, et al. 2008) 
Developing / Emerging Countries -Ensuring a Worldwide Collection
Although ~90% of known SNPs are shared between Asians, Europeans and Africans, 80% of private SNPs are found within Asian and Africans (Hinds, et al., 2005; Jorde and Wooding, 2004) . The recent sequencing of the Watson (Wheeler, et al., 2008) , Venter (Levy, et al., 2007) , Kriek (http://www.sciencedaily.com/releases/2008/05/080526155300.htm), West African (Bentley et al., 2008) and Han Chinese (Wang et al., 2008) genomes, along with gene specific re-sequencing efforts (see Introduction), suggest that a large number of SNPs and other sequence variation exists in the human population. Estimates from African genetic diversity and the Pan Asian SNP initiative suggest that 80 to 90% of human genomic variation resides in the world's emerging countries. Any formal attempt to identify the extent of genomic variation must include geographical regions which have not been included in haplotype mapping projects. Although the Population Reference Sample (POPRES) will address some of these missing populations , this effort is designed as a mapping project, not one focused on functional polymorphisms or mutations. Hence, the main focus of the HVP effort is the inclusion and analyses of clinical samples from diverse ethnic groups.
The distinct advantage of some ethnic populations is the opportunity to study genetic diseases due to consanguinity, large family size, and potential founder effects (e.g., Bittles 2001; Bittles 2002; Saadallah and Rashed, 2007) . Emerging nations will be regarded as major contributors to the VARIOME project.
However, biomedical research has not been the focus of resource poor countries even though such activities are likely to produce economic and health benefits for all (Daar et al., 2002; Singer and Daar, 2001 ). Education of healthcare providers, the public, and government officials is needed for demonstrating the universal nature of the HVP, the need to include populations in developing countries, and the benefits from cooperating in biomedical research (Bhan et al., 2007; Cohen et al., 2008; Seguin et al., 2008; Tindana et al., 2007) . Certain populations may mistrust research involving genetic analyses or fear that results can be misused to support discrimination or worse (http://www.eubios.info/ASIAE/BIAE201.htm): Malay-Muslims, Chinese, and Indians in Singapore expressed anxiety about breach of confidentiality, the misuse of their DNA for cloning, and possibilities of being diagnosed with disease (Wong et al., 2004) . Community based participatory research collaborations may provide forums for addressing cultural and ethical concerns of biomedical research (McCabe-Sellers et al., 2008) .
Analyzing the extent of human genomic variation creates an ideal opportunity for the developed and the developing nations of the world to forge meaningful partnerships and to work together in an unprecedented way, initially to identify variation causing disease, and then to understand how general variation contributes to human phenotypic diversity. By ensuring that all nations and ethnic groups have an equal and fair opportunity to share data and technology, we will provide evidence-based information that all populations can benefit from a global society health network. The primary objectives for including populations in emerging countries are described in Box 6.
The HVP appreciates the genomic sovereignty/equality for all countries to be involved in the Human Variome Project and acknowledges the value of 'human capital' within all populations. Real and tangible benefits of the HVP to improve health will be generated for participating populations; the voluntary participation of the greatest number of countries would ensure a more general applicability and it is hoped that many countries will decide to participate.
Progress in Developing Ethical Guidelines for LSDBs: Principles to Practice to Implementation
Ethical issues remain of vital concern to the Human Variome Project. Participating researchers are committed to adhering to the highest ethical principles governing research, data sharing and ultimately enabling this new knowledge to benefit all of humanity as much as possible. Ethical guidelines specifically for LSDBs were previously published (Cotton et al., 2005) .
LSDBs may contain a large amount of phenotypic data. Most LSDBs post a considerable amount of data on public websites and increasingly this information may be accessible through genome browsers. While the best intention of the HVP is to ensure that participants are acknowledged as a group, without any risk of identification, a specific challenge occurs in the case of rare mutations associated with distinctive clinical features. Since epistatic and environment interactions (reviewed in Kaput, 2008) alter age of onset, severity, complications and outcomes for monogenic and polygenic phenotypes, it may be necessary to analyze entire genomes for personalized healthcare. Such polygenic analyses generate data that could be used for re-identifying individual patients (Craig et al., 2008) .
Other ethical concerns may be minimized by improving communication about the project and its goals through multiple channels such as print and broadcast media, local community outreach, and internet sources such as the HGVS website. The HVP will develop an ethics review committee with a subcommittee focused on issues related to LSDB for (i) providing counsel when dilemmas arise, (ii) overseeing guidelines, (iii) identifying best practices, (iv) determining how best to ensure privacy in all situations, (v) formulating how to handle data for which explicit consent does not exist or is not possible to achieve, and (vi) developing a consent form that is consistent for all LSDBs but which can be adapted to the requirements of individual countries. Such consent would contain, for example, a re-contact clause.
The specific recommendation and open questions are outlined in Box 7.
The HVP, through its Ethics Working Group, is committed to (i) soliciting, collecting and analyzing consent forms in order to develop a model consent form that can provide greater consistency across all LSDBs, (ii) seeking the input of relevant clinical genetic societies for comment, and (iii) using that input to develop ethical standards for LSDBs.
Funding Mechanisms and Governance
Funding for collecting data of mutations causing single gene disorders has traditionally been difficult due to the extreme fragmentation of the field even though mutations affect 60% of all individuals in a lifetime (Baird, et al., 1988) . The funding possibilities are more likely if the international HVP is treated as a concerted effort. Given the limitations of existing knowledge (see Introduction and Patrinos and Brookes, 2005) , this initiative will benefit research in many fields and impact prevention and clinical care of disease.
Specific focus areas for developing funding streams are described in Box 8.
Governance. Those dedicated to assisting themselves and others in their clinics by collecting mutation/variants causing inherited disease have in the past acted in isolation; reinventing wheels wastes funds and time. The HGVS, formerly HUGO-MDI, was formed to alleviate this problem and accelerate the collection and management of information on mutation causing disease(s). The HVP was named and initiated to define the aims of this activity (Melbourne in 2006) by an extremely high profile group of experts in all types of genetic variation analyses. The Genomic Disorders Research Center (Melbourne, Australia; http://www.genomic.unimelb.edu.au) was voted as coordinating office, to continue its function of facilitating independent projects started at the inception of the centre in 1996. In association with world experts, Deloitte (http://www.deloitte.com) developed a business plan, which was approved by the HVP Planning Group. The HVP Planning Meeting was a designated activity of this plan and other sections of the plan will follow (e.g. board function to oversee the coordinating office's function and support it). The business plan calls for a broadly defined community of interested stakeholders to develop the HVP (Box 9).
Open questions that must be resolved in future meetings are (i) the extent of data sharing between patient records and research databases, (ii) appropriate descriptions of data elements, and (iii) data ownership and confidentiality.
Pilot Projects
The HVP has established a partnership with the International Society for Gastrointestinal Hereditary Tumors (InSiGHT; http://www.insight-group.org) to collect and classify a large set of missense variants associated with hereditary colorectal cancer. This effort will develop HVP's prototype system for interpreting variants observed in clinical genetic testing (Box 10). InSiGHT consists of a multidisciplinary scientists focused particularly on the Mendelian disorders predisposing to colorectal cancer (Familial Adenomatous Polyposis, Lynch Syndrome and MUTYH related polyposes). This effort is an ongoing project but also a model or pilot for the HVP. InSiGHT has conducted several multidisciplinary studies of Hereditary Non Polyposis Colon Cancer (HNPCC) patients that (i) require the development of a disease-specific model for integrating databases across laboratories, (ii) establish standards for data consistency for phenotypes (which include graphic pedigrees), (iii) address confidentiality, and (iv) develop a template for consent. Clinicians from multiple countries and regions are contributing and committing to the development of these systems. Some of these issues cross disciplinary boundaries and are being addressed by other committees of the HVP. The InSiGHT consortium's roadmap includes providing access to clinicians, a vital resource that will serve patients in the immediate future, and as a model for other genes and phenotypes. Among the first efforts involved uploading large datasets of mismatch repair variants generated by national consortia and laboratories into the InSiGHT MMR, a LSDB which uses the LOVD platform. Data transfer into a mirrored central database (e.g., NCBI or EBI) is also planned with an initial reciprocal agreement with the Health Data Integration project at the Australian CSIRO Centre 
Discussion
The vision of the HVP, to catalogue and access all information related to human disease variation, is ambitious. One can conceptualize the challenge as a multi-dimensional, fluid matrix, with all ~20,000 genes as column headings and rows of potentially thousands of variants as descriptors. In addition, third and further dimensions would annotate other biological parameters, for example clinical and/or metabolic phenotype, microarray expression, proteomics, protein interactions, nutrient intakes, physical activity, and other functional phenotypic and epidemiological data. Separate dimensions that must be linked to these variants are the main effect of gene -environment interactions (e.g., Lim et al., 2007) . These data elements relate to the cells in the initial two dimensional matrix since each may affect the genetic expression of the mutation or gene variant. These dimensions are domains of knowledge that must be integrated for understanding biological processes.
A predetermined bioinformatics structure to accommodate this matrix with forced fields for data entry is notionally appealing but practically impossible. The reality is that LSDBs, which capture the core information in any one of these domains of information, are developed by experts and curated with invaluable skill and experience. To force any change on these individual efforts would risk inestimable loss of activity by the curators and threaten data of individuals in populations. The challenge then is to integrate the existing and developing information within existing databases and public resources into a system based on this matrix of domains -the vision of the HVP.
The task of developing "super searching" software to interrogate the global information and relate it across the HVP matrix in a user-friendly fashion for enquiry represents a bioinformatics challenge already embraced by the numerous national projects (e.g., Stein, 2008) . This challenge can be met with resources applied to software development or existing applications that allow searches to locate all information across all domains of the international data matrix. Hansen's SRS (sequence retrieval system) approach (http://e-hrc.net/hdi/), or the novel Genome Commons Navigator (Brenner, 2007) , supported the Berkeley Computational Biology Center (http://ccb.berkeley.edu/ccb/index.html), both target this concept. The Navigator also seeks to provide algorithms for potential interpretation of pathogenicity.
The approaches presented at the HVP planning meeting contribute to this goal of integrating biological information. The HVP efforts are also consistent with the newly emerging initiative to develop standards for scientific disciplines and research strategies: the MIBBI Project (minimal reporting guidelines for biological and biomedical investigations; Taylor, 2007; Taylor et al., 2008) . The challenge to catalogue and access this vast body of information relating to human biology and behavior is immense, but the HVP is leading this endeavor through international collaborations and harmonized protocols. The development of this network of LSDBs and the knowledge they generate and maintain will be beneficial not only for the genetic research community, but also for researchers in nutrition, toxicology, teratology, physiologyvirtually all biological research arenas, but perhaps most importantly for the translation of basic research for improving personal and public health. The future is indeed exciting.
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